Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2026-11-20
Target enrollment:
Participant gender:
Summary
Immunotherapy with programmed death-1(PD-1) inhibitors is now standard therapy for first-line
use in patients with driver-negative advanced NSCLC, whether as single-agent or in
combination with chemotherapy. After progression of first-line immunotherapy, NSCLC patients
may be treated with chemotherapy, radiotherapy or targeted therapies, among others. Recently,
Immune Checkpoint inhibitors (ICIs) rechallenge has become a highly anticipated option.
Although the objective response rate of the ICIs rechallenge patients has decreased
substantially compared with the efficacy of the first ICI treatment, nearly 50% of patients
can regain disease control.
Cryoablation is a minimally invasive technique that utilizes very low temperature to
eliminate viable tumour cells in target tissues. It has been reported that ablation can
enhance immune response.
The objective of this study was to evaluate the efficacy and safety of toripalimab (PD-1) in
combination with cryoablation in the treatment of oligometastatic driver-negative advanced
NSCLC after first-line immunotherapy progress.